002873 Guiyang Xintian Pharmaceutical
- 11.39
- -0.20-1.73%
Guiyang Xintian Pharmaceutical News
Xintian Pharmaceutical (002873.SZ): As of May 10, 2024, the number of shareholders of the company was 18,111
Gelonghui, May 13 | Xintian Pharmaceutical (002873.SZ) said on the investor interactive platform that as of May 10, 2024, the number of shareholders of the company was 18,111.
Xintian Pharmaceutical (002873.SZ) spent 753.04 million yuan to complete the repurchase of 3.80% of shares
Xintian Pharmaceutical (002873.SZ) issued an announcement. As of February 8, 2024, the company has passed a share repurchase special...
Xintian Pharmaceutical (002873.SZ): Net profit of 15.571,600 yuan in the first quarter decreased by 37.94% year-on-year
Gelonghui, April 26 | Xintian Pharmaceutical (002873.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 177 million yuan, down 15.06% year on year; net profit attributable to shareholders of listed companies was 15.571,600 yuan, down 37.94% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 147.152 million yuan, down 38.53% year on year; basic earnings per share were 0.0673 yuan.
Tianfeng Securities released a research report on April 18 stating that it gave Xintian Pharmaceutical (002873.SZ) an increase in holdings rating. The main reasons for the rating include: 1) revenue pressure on core products; 2) marketing system reforms a
Tianfeng Securities released a research report on April 18 stating that it gave Xintian Pharmaceutical (002873.SZ) an increase in holdings rating. The main reasons for the rating include: 1) revenue pressure on core products; 2) marketing system reforms are showing initial results, and costs have been optimized; 3) epitaxial expansion is expected to form a “traditional Chinese medicine+chemical medicine” dual-track pattern. (Mainichi Keizai Shimbun)
Xintian Pharmaceutical (002873): Short-term performance is under pressure, marketing system reform is beginning to bear fruit
Incident: On April 12, 2024, Xintian Pharmaceutical disclosed its 2023 annual report. In 2023, the company achieved operating income of 954 million yuan, -12.29% year-on-year; achieved net profit of 81 million yuan to mother
Xintian Pharmaceutical (002873.SZ): Strategically invested in Huilun Pharmaceutical, the current shareholding ratio is 14.88%
Gelonghui, April 17 | Xintian Pharmaceutical (002873.SZ) said on the investor interactive platform that the company's strategic investment in Huilun Pharmaceutical currently has a shareholding ratio of 14.88%. According to relevant accounting policy regulations, it has not yet been included in the scope of the company's consolidated statements, and changes in its operating performance will not have a significant impact on the company's 2023 net profit and other indicators. According to a thorough understanding of the business situation of Huilun Pharmaceutical Company, it is a high-tech enterprise dedicated to R&D and technical services for small molecule innovative drugs and generic drugs. The industrialization and commercialization process of its chemical products has been steady, and its business has grown rapidly in the past three years. 2
Xintian Pharmaceutical (002873): Performance under phased pressure continues to consolidate core competitiveness and unleash growth potential
The company's performance is under phased pressure, and the adjustment cost investment focuses on long-term development. The company released its 2023 annual report: in 2023, the company achieved operating income of 954 million yuan (-12.29%) and net profit of 81 million yuan to mother (-
China Post Securities released a research report on April 12 stating that it gave Xintian Pharmaceutical (002873.SZ) a purchase rating. The main reasons for the rating include: 1) the company's performance is under phased pressure, and cost investment is
China Post Securities released a research report on April 12 stating that it gave Xintian Pharmaceutical (002873.SZ) a purchase rating. The main reasons for the rating include: 1) the company's performance is under phased pressure, and cost investment is being adjusted to focus on long-term development; 2) channel expansion is being further promoted, production capacity is continuously strengthened, and core competitiveness is continuously consolidated; 3) the intention to control Huilun Pharmaceutical through equity acquisition to deepen the small molecule chemical business layout, which is expected to enhance the company's performance. (Mainichi Keizai Shimbun)
Xintian Pharmaceutical (002873.SZ) announced its 2023 annual results, net profit of 808.711 million yuan, a decrease of 27.48%
Xintian Pharmaceutical (002873.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 954 million yuan, a year-on-year decrease of 12.29%. Net profit attributable to shareholders of listed companies was RMB 808.711 million, a year-on-year decrease of 27.48%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 750.95 million yuan, a year-on-year decrease of 25.87%. Basic earnings per share were $0.3489. It is proposed to distribute a cash dividend of 0.70 yuan (tax included) for every 10 shares to all shareholders.
Xintian Pharmaceutical (002873.SZ): As of April 10, 2024, the number of shareholders in the company was 18,837
Gelonghui, April 11 | Xintian Pharmaceutical (002873.SZ) said on an interactive platform that as of April 10, 2024, the number of shareholders of the company was 18,837.
Express News | Xintian Pharmaceutical establishes a subsidiary business including drug Internet information services
The A-share Chinese medicine sector declined, and Xiangxue Pharmaceutical fell more than 5%
Gelonghui, March 13 | Datang Pharmaceutical and Xiangxue Pharmaceutical fell more than 5%, while Xintian Pharmaceutical, Biogu, Weikang Pharmaceutical, Teyi Pharmaceutical, and Xinguang Pharmaceutical followed suit.
A-share traditional Chinese medicine stocks opened actively, and Forci Pharmaceuticals rose or stopped
Gelonghui, March 12 | Foci Pharmaceutical and Xintian Pharmaceutical rose and stopped, Zoli Pharmaceutical rose more than 15%, and Guangdong Wannianqing, Taiji Group, and Panlong Pharmaceutical followed suit. According to the news, Forci Pharmaceuticals announced that due to reasons such as rising raw materials and production costs, the company decided to adjust the factory price of its main proprietary Chinese medicine products starting March 11, 2024, with an average price increase of 9%. In addition, Zuoli Pharmaceuticals expects net profit of 137 million yuan to 147 million yuan for the first quarter, an increase of 40.58%-50.84% over the previous year.
Xintian Pharmaceutical (002873): Proposed acquisition of Huilun Pharmaceutical to deepen the small molecule chemical sector layout and continue to consolidate core competitiveness and unleash growth potential
It plans to control Huilun Pharmaceutical through the acquisition of shares to deepen the small-molecule chemical business layout, which is expected to increase the company's performance. On March 7, the company issued an announcement stating that it is planning to share some shares in Shanghai Huilun Pharmaceutical Co., Ltd. (hereinafter referred to as “Huilun Pharmaceutical”)
Xintian Pharmaceutical (002873.SZ): Trading of the company's shares and convertible bonds will resume on March 8
Gelonghui, March 7, 丨 Xintian Pharmaceutical (002873.SZ) announced that following the company's application to the Shenzhen Stock Exchange, trading of the company's shares and convertible corporate bonds will resume trading from the opening of the market on March 8, 2024 (Friday), and convertible corporate bonds will resume conversion on the same day.
Express News | Xintian Pharmaceutical: Plans to purchase 85.12% of Huilun Pharmaceutical's shares through the issuance of shares
Xintian Pharmaceutical (002873.SZ): 3.8037% of shares have been cumulatively repurchased
Gelonghui, March 1, 丨 Xintian Pharmaceutical (002873.SZ) announced that as of February 29, 2024, the company had repurchased a total of 8,806,030 shares through a special share repurchase account, accounting for 3.8037% of the company's total share capital of 231,514,155 shares on February 29, 2024. The maximum transaction price was 9.40 yuan/share, and the minimum transaction price was 7.67 yuan/share. The total amount paid was 75,303,968.97 yuan (including transaction fees).
Xintian Pharmaceutical (002873.SZ): Shuofang Pharmaceutical passed the high-tech enterprise certification
Gelonghui, Feb. 29丨Xintian Pharmaceutical (002873.SZ) announced that Shanghai Shuofang Pharmaceutical Technology Co., Ltd. (“Shuofang Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” jointly issued by the Shanghai Municipal Science and Technology Commission, the Shanghai Finance Bureau, and the Shanghai Taxation Bureau of the State Administration of Taxation, which has passed the certification of a high-tech enterprise.
Express News | Xintian Pharmaceutical: Obtained 13 trademark registration certificates
Xintian Pharmaceutical (002873) Company Information Update Report: Proposed acquisition of Huilun Pharmaceutical to further expand the commercial footprint of small molecule chemicals
Xintian Pharmaceutical plans to acquire Huilun Pharmaceutical and expand the small molecule chemical business map company issued an announcement stating that it is planning to issue shares to some shareholders of Huilun Pharmaceutical in Shanghai to purchase part of Huilun Pharmaceutical's shares and establish control over Huilun Pharmaceutical. up to 202
Analysis
Price Target
No Data
